MannKind (NASDAQ:MNKD) Rating Increased to Buy at HC Wainwright

MannKind (NASDAQ:MNKD) was upgraded by HC Wainwright to a “buy” rating in a research note issued to investors on Wednesday, Marketbeat.com reports. The brokerage presently has a $9.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 134.07% from the stock’s current price. HC Wainwright also issued estimates for MannKind’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.05 EPS.

MNKD has been the subject of several other research reports. Mizuho started coverage on shares of MannKind in a research report on Thursday, April 10th. They issued an “outperform” rating and a $12.00 price target for the company. Wall Street Zen lowered shares of MannKind from a “buy” rating to a “hold” rating in a research report on Friday, June 27th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, MannKind currently has an average rating of “Buy” and an average target price of $10.14.

MannKind Stock Performance

Shares of MNKD traded down $0.06 during trading hours on Wednesday, reaching $3.85. 281,462 shares of the company traded hands, compared to its average volume of 2,423,601. The stock’s fifty day moving average is $4.03 and its 200 day moving average is $4.90. The stock has a market cap of $1.17 billion, a P/E ratio of 38.46 and a beta of 0.96. MannKind has a 1-year low of $3.51 and a 1-year high of $7.63.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. The business had revenue of $78.35 million during the quarter, compared to analyst estimates of $75.86 million. MannKind had a net margin of 10.12% and a negative return on equity of 32.41%. The firm’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.05 earnings per share. On average, equities research analysts predict that MannKind will post 0.1 EPS for the current year.

Insider Activity

In other MannKind news, EVP David Thomson sold 32,179 shares of the company’s stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $4.68, for a total transaction of $150,597.72. Following the sale, the executive vice president directly owned 772,427 shares of the company’s stock, valued at approximately $3,614,958.36. This represents a 4.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steven B. Binder sold 75,367 shares of the company’s stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $3.94, for a total transaction of $296,945.98. Following the sale, the director directly owned 830,508 shares in the company, valued at $3,272,201.52. This represents a 8.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 266,198 shares of company stock worth $1,143,244 over the last ninety days. Insiders own 2.70% of the company’s stock.

Institutional Trading of MannKind

Several large investors have recently added to or reduced their stakes in MNKD. Xponance Inc. grew its stake in shares of MannKind by 10.6% during the fourth quarter. Xponance Inc. now owns 19,067 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 1,828 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of MannKind by 4.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 60,895 shares of the biopharmaceutical company’s stock valued at $306,000 after purchasing an additional 2,420 shares during the last quarter. E Fund Management Co. Ltd. grew its stake in shares of MannKind by 11.9% during the first quarter. E Fund Management Co. Ltd. now owns 24,667 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 2,628 shares during the last quarter. Summit Investment Advisors Inc. grew its stake in shares of MannKind by 10.4% during the fourth quarter. Summit Investment Advisors Inc. now owns 28,174 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 2,657 shares during the last quarter. Finally, AXQ Capital LP grew its stake in shares of MannKind by 19.8% during the fourth quarter. AXQ Capital LP now owns 22,530 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 3,717 shares during the last quarter. 49.55% of the stock is owned by institutional investors.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.